Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis
Reference (14)
- et al.
Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis: results of a double-blind clinical trial
Am J Med
(1985) - et al.
Inhibition of calcium ionophore (A23187)-stimulated histamine release from rat peritoneal mast cells by azelastine: implications for its mode of action
Eur J Pharmacol
(1983) - et al.
Azelastine inhibition of skin test reactivity in humans [Abstract]
J Allergy Clin Immunol
(1985) - et al.
Analysis of plasma histamine levels in patients with mast cell disorders
Am J Med
(1989) - et al.
Analysis of the wheal-and-flare reactions that follow the intradermal injection of histamine and morphine in adults with recurrent, unexplained anaphylaxis and systemic mastocytosis
J Allergy Clin Immunol
(1989) - et al.
Measurement of plasma histamine: description of an improved method and normal values
J Allergy Clin Immunol
(1982) - et al.
Azelastine's therapeutic action in asthma [Abstract]
J Allergy Clin Immunol
(1988)
Cited by (38)
The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome
2020, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :N-MH excretion also correlated with serum tryptase values.105 Treatment of symptoms in SM with antihistamines has shown approximately equal effectiveness of azelastine and chlorpheniramine, though azelastine was superior to chlorpheniramine in suppressing skin responses to histamine and morphine sulfate and in suppressing pruritus.106 Control of SM symptoms with cromolyn sodium or the combination of chlorpheniramine and cimetidine is approximately equal.107
Antihistamines
2020, Comprehensive Dermatologic Drug Therapy, Fourth EditionGastrointestinal Involvement in Mast Cell Activation Disorders
2018, Immunology and Allergy Clinics of North AmericaCitation Excerpt :In addition to being an H1 blocker, ketotifen and desloratadine may also decrease mast cell mediator release, although ketotifen has not been shown to be superior to traditional H1 antagonists in mastocytosis.48–50 It may be the H2 antagonists that provide the most GI symptom relief in systemic mastocytosis; although some earlier studies have suggested that H1 antagonists may improve GI symptoms, a more recent double-blind, placebo-controlled study of the second-generation dual H1 receptor/platelet activating factor antagonist rupatadine in adult mastocytosis subjects found statistically significant improvement in the treatment group for a large number of clinical symptom parameters except for GI symptoms.50–53 Abdominal cramping and diarrhea may be responsive to oral cromolyn sodium.54
Anti-H1 in dermatological practice
2005, Annales de Dermatologie et de VenereologieInvolvement of central μ-opioid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system
2003, European Journal of PharmacologyHistamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis
2003, Annals of Allergy, Asthma and Immunology